GlassScriptPhysician profile
Farah Monzur
NPI 1447575667
$110,804.58
in general payments reported to CMS, 2019-2025
31 companies · $1,733 in 2025
The $1,733 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,495 · 2020: $27K · 2021: $33K · 2022: $4,138 · 2023: $16K · 2024: $28K · 2025: $1,733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Travel and Lodging: $14K · Food and Beverage: $4,852 · Education: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,390.00 |
| Travel and Lodging | $13,826.90 |
| Food and Beverage | $4,851.91 |
| Education | $331.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $55,759.18 | 2021-2024 | Gi Genius, Pillcam |
| Covidien LP | $26,030.00 | 2020 | |
| Celltrion USA INC. | $19,228.12 | 2024 | Zymfentra |
| Abbvie INC. | $4,029.19 | 2019-2025 | |
| Janssen Biotech, INC. | $1,994.53 | 2019-2025 | Stelara, Tremfya |
| Intercept Pharmaceuticals, INC. | $517.40 | 2021-2025 | Ocaliva |
| Pfizer INC. | $437.98 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $377.51 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $356.70 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Lilly USA, LLC | $242.11 | 2024-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $235.79 | 2021 | |
| Celgene Corporation | $233.62 | 2021-2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $176.41 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $150.95 | 2019-2023 | Linzess |
| Merck Sharp & Dohme LLC | $144.10 | 2019-2024 | Dificid |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $142.62 | 2022 | |
| Phathom Pharmaceuticals, INC. | $109.76 | 2024 | Voquezna |
| Ardelyx, INC. | $86.79 | 2025 | Ibsrela |
| Daiichi Sankyo INC. | $84.66 | 2019-2022 | |
| Genzyme Corporation | $65.33 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.70 | 2022-2024 | Xifaxan |
| Mallinckrodt Hospital Products INC. | $63.53 | 2024-2025 | Terlivaz |
| Madrigal Pharmaceuticals | $63.06 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $51.82 | 2024-2025 | Livdelzi |
| Shire North American Group INC | $38.81 | 2019 | |
| Alnylam Pharmaceuticals INC. | $26.39 | 2024 | Givlaari |
| Nestle Healthcare Nutrition INC. | $24.61 | 2021 | |
| Olympus America INC. | $20.48 | 2025 | Endoclot Sis |
| Allergan, INC. | $20.00 | 2019 | |
| Alfasigma USA, INC. | $16.83 | 2020 | |
| Dynavax Technologies Corporation | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farah Monzur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.